Ohcanbohtosat - Ray Lin

  • Čájehuvvo 1 - 5 / 5
Aiddostahte ozu
  1. 1
    NMDA Receptors Mediate Olfactory Learning and Memory in Drosophila

    NMDA Receptors Mediate Olfactory Learning and Memory in Drosophila Dahkki Shouzhen Xia, Tomoyuki Miyashita, Tsai‐Feng Fu, Wei‐Yong Lin, Chia‐Lin Wu, Lori Pyzocha, Inn-Ray Lin, Minoru Saitoe, Tim Tully, Ann‐Shyn Chiang

    Almmustuhtton 2005
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

    Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors Dahkki Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra Sanabria Bohórquez, Heidi Savage, Deepak Sampath, Laurent Salphati, Ray Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors Dahkki Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono

    Almmustuhtton 2014
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors Dahkki Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene P. Kennedy, Mario R. Mautino, Charles J. Link, Ray Lin, Stephanie Royer‐Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors Dahkki Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Michael A. Gordon, Yung‐Jue Bang, Matthew D. Hellmann, Andrés Cervantes, María Ochoa de Olza, Aurélien Marabelle, F. Stephen Hodi, Myung‐Ju Ahn, Leisha A. Emens, Fabrice Barlési, Omid Hamid, Emiliano Calvo, David F. McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Lew Tsuhako, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis

    Almmustuhtton 2019
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: